Fig. 3

Effects of clemastine short treatment on SOD1 and SQSTM1/p62 protein levels in symptomatic SOD1-G93A mice. a Representative images of total lumbar spinal cord lysates from vehicle- and clemastine- treated SOD1-G93A mice at PND 120 subjected to western blotting under non-reducing conditions with anti-SOD1 and anti-GAPDH for protein normalisation. b Quantitative analysis of mutant SOD1 monomer band density in mice lumbar spinal cords. Data represent mean ± S.E.M. Statistical significance was calculated by student’s t test, as referred to vehicle-treated SOD1-G93A mice, * p < 0.05. c Equal amounts of total lumbar spinal cord lysates from WT mice (~120 days) and vehicle- or clemastine-treated SOD1-G93A mice (n = 4/group) are subjected to western blotting with anti LC3-I/II or in d with anti-SQSTM1/p62. Anti-GAPDH is used for protein normalisation. Data represent mean ± S.E.M. Statistical significance was calculated by student’s t test, as referred to WT, or to vehicle-treated SOD1-G93A mice, * p < 0.05